RecruitingNCT05507879

TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study)

Sponsor

Mayo Clinic

Enrollment

200 participants

Start Date

Sep 26, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Carcinoma Cardiomyopathy Congestive Heart Failure

Summary

This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer. Cardiac toxicity, changes in heart function is a well-recognized complication of certain cancer related therapies. Understanding these changes may allow early intervention against therapy-related cardiac toxicity and also identify novel therapeutic targets to protect patient long-term cardiac health. Studying samples of blood from patients with breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA), identify biomarkers related to cardiac toxicity, and prevent the development of therapy-induced cardiac toxicity in patients receiving chemotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether a protein called TRPC6 found in the blood can predict which breast cancer patients are at risk of developing heart problems from chemotherapy drugs like doxorubicin (an anthracycline) or trastuzumab (Herceptin). Heart damage from chemotherapy is a serious side effect, and this study aims to find a way to identify and protect at-risk patients earlier. **You may be eligible if...** - You are 18 years or older - You have breast cancer and are about to start chemotherapy with doxorubicin or another anthracycline, or are receiving trastuzumab without anthracyclines - You are receiving this treatment before or after surgery (neoadjuvant or adjuvant setting) - You understand the study and are willing to participate **You may NOT be eligible if...** - You already have significant pre-existing heart disease - You are unable to provide informed consent - You have already completed chemotherapy - You have contraindications to the required heart monitoring tests Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.